Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Omeros Corporation (OMER : NSDQ)

• Company Description    Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. Number of Employees: 213

• Price / Volume Information    Yesterday's Closing Price: $2.81 Daily Weekly Monthly 20 Day Moving Average: 899,329 shares Shares Outstanding: 62.73 (millions) Market Capitalization: $176.27 (millions) Beta: 0.82 52 Week High: $16.62 52 Week Low: $2.50 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -31.63% -23.00% 12 Week -59.63% -55.62% Year To Date -56.30% -45.27%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 201 ELLIOT AVENUE WEST - SEATTLE,WA 98119 USA ph: 206-676-5000 fax: 206-676-5005 None http://www.omeros.com

• General Corporate Information    Officers Gregory A. Demopulos - President; Chief Executive Officer and Chairman of Michael A. Jacobsen - Vice President; Finance; Chief Accounting Officer Thomas F. Bumol - Director Thomas J. Cable - Director Peter A. Demopulos - Director Peer Information Omeros Corporation (BJCT) Omeros Corporation (CADMQ) Omeros Corporation (APNO) Omeros Corporation (UPDC) Omeros Corporation (IMTIQ) Omeros Corporation (CYGN) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 682143102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 62.73 Most Recent Split Date: (:1) Beta: 0.82 Market Capitalization: $176.27 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.70 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.27 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 1.95 EPS Growth vs. Year Ago Period: -12.00% vs. Previous Quarter: -51.35% Sales Growth vs. Year Ago Period: 14.90% vs. Previous Quarter: 4.10% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - -37.53 12/31/21 - -44.68 09/30/21 - -69.20 Current Ratio 03/31/22 - 5.99 12/31/21 - 4.79 09/30/21 - 2.13 Quick Ratio 03/31/22 - 6.00 12/31/21 - 4.79 09/30/21 - 2.12 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - -116.83 Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - -136.61 Pre-Tax Margin 03/31/22 - -308.14 12/31/21 - - 09/30/21 - -192.37 Book Value 03/31/22 - -0.08 12/31/21 - 0.38 09/30/21 - -4.20 Inventory Turnover 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.17 Debt-to-Equity 03/31/22 - - 12/31/21 - 13.18 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - 92.95 09/30/21 - -

Powered by Zacks Investment Research ©